Efficacy And Safety Of Bevaxizumab Combined With FOLFIRI Or CAPIRI For Advanced Metastatic Colorectal Cancer:a Meta-analysis

Objective To assess the effectiveness and safety of FOLFIRI(fluorouracil combined with irinotecan)+ Bevacizumab versus CAPIRI(capacitance combined with irinotecan)+ Bevacizumab for patients with advanced metastatic colorectal cancer(m CRC).Methods A search of randomized clinical trials(RCTs)using FOLFIRI+Bev and CAPIRI+ Bev to cure m CRC was performed in the Cochrane Library?Pub Med?Embase?CNKI?VIP and Wan Fang databases.We evaluated the quality of RCTs and then extracted data from each study.The software Stata 15.0 was used for meta-analysis.Primary outcomes were progressionfree survival(PFS)and overall survival(OS).Secondary outcomes were objective response rate(ORR)?disease control rate(DCR)and toxicity.Results 3 RCTs containning 763 patients were involved.The analysis result showed that FOLFIRI+Bev was superior to CAPIRI+Bev regimen in the DCR[RR=1.10,95%CI:(1.01,1.21),P=0.028].There was no significant difference in CR?ORR?PFS?OS between the two regimens.FOLFIRI+ Bev regimen had less opportunity in Febrile neutropenia[RR=0.36,95%CI:(0.13,0.98),P=0.046]?diarrhea[RR=0.55,95%CI:(0.37,0.82),P=0.003],but more in Neutropenia[RR=1.48,95%CI:(1.10,1.98),P =0.009].Conclusion FOLFIRI+ Bev regimen was effective for advanced colorectal cancer,and might be a recommended chemotherapy regimen.